Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Federico

Showing results (101-110 of 271) with videos related to

Pageof 28
Sort By:
British Journal of Haematology|March 31, 2015
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana LinfomiLuigi Marcheselli, Alessia Bari, Antonella Anastasia, et al.
Journal of Cancer Research and Clinical Oncology|May 2, 2013
Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patientsFrancesca Bella, Pamela Minicozzi, Adriano Giacomin, et al.
Tumori|October 26, 2013
Estimates of cancer burden in Emilia-RomagnaFabio Falcini, Silvia Mancini, Alessandra Ravaioli, et al.
British Journal of Haematology|May 16, 2020
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphomaFulvio Massaro, Yana Stepanishyna, Martina Manni, et al.
Blood Advances|January 8, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international studyElizabeth H Phillips, Nicholas Counsell, Tim Illidge, et al.
Leukemia & Lymphoma|December 30, 2009
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio LinfomiDonato Mannina, Stefano Luminari, Alessandra Dondi, et al.
Haematologica|November 13, 2008
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term resultsAngelo Michele Carella, Monica Bellei, Pauline Brice, et al.
British Journal of Haematology|October 28, 2016
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patientsAlessia Bari, Luigi Marcheselli, Raffaella Marcheselli, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
Relative and disease-free survival for breast cancer in relation to subtype: a population-based studyPamela Minicozzi, Francesca Bella, Angela Toss, et al.
Tumori|June 9, 2012
Differences in stage and treatment of breast cancer across Italy point to inequalities in access to and availability of proper carePamela Minicozzi, Claudia Cirilli, Massimo Federico, et al.
Pageof 28

Showing results (101-110 of 271) with videos related to

Sort By:
Pageof 28
British Journal of Haematology|March 31, 2015
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana LinfomiLuigi Marcheselli, Alessia Bari, Antonella Anastasia, et al.
Journal of Cancer Research and Clinical Oncology|May 2, 2013
Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patientsFrancesca Bella, Pamela Minicozzi, Adriano Giacomin, et al.
Tumori|October 26, 2013
Estimates of cancer burden in Emilia-RomagnaFabio Falcini, Silvia Mancini, Alessandra Ravaioli, et al.
British Journal of Haematology|May 16, 2020
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphomaFulvio Massaro, Yana Stepanishyna, Martina Manni, et al.
Blood Advances|January 8, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international studyElizabeth H Phillips, Nicholas Counsell, Tim Illidge, et al.
Leukemia & Lymphoma|December 30, 2009
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio LinfomiDonato Mannina, Stefano Luminari, Alessandra Dondi, et al.
Haematologica|November 13, 2008
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term resultsAngelo Michele Carella, Monica Bellei, Pauline Brice, et al.
British Journal of Haematology|October 28, 2016
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patientsAlessia Bari, Luigi Marcheselli, Raffaella Marcheselli, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
Relative and disease-free survival for breast cancer in relation to subtype: a population-based studyPamela Minicozzi, Francesca Bella, Angela Toss, et al.
Tumori|June 9, 2012
Differences in stage and treatment of breast cancer across Italy point to inequalities in access to and availability of proper carePamela Minicozzi, Claudia Cirilli, Massimo Federico, et al.
Pageof 28